Activation of HCA1 in adipocytes by lactate results in the inhibition of lipolysis at physiologically relevant lactate concentrations (1 to 20 mM) [1], suggesting that HCA1 could be a new target for dyslipidemia treatment without the unwanted side effect of cutaneuous flushing. Here, HCAR1 is linked to metabolic syndrome.